Familial amyloid polyneuropathy (FAP; also known as familiar amyloidosis and hereditary amyloidosis) is an autosomal dominant inherited disease due to mutations of the transthyretin (TTR) gene coding for the corresponding protein, consisting of 127 amino acids. The gene is located on chromosome 18q. More than 100 different mutations are known. Other mutant precursor proteins produced in the liver, such as apolipoprotein I and II, lysozyme and fibrinogen Aα, may be of etiological importance as well. Amyloidogenic mutations of the TTR gene lead to decreased stability of the corresponding protein and subsequently to extracellular deposition of amyloid in several tissues (peripheral and autonomic nerves, walls of the gastrointestinal tract, heart, etc.). The Val30Met mutation is the most prevalent cause of FAP worldwide. There are endemic regions in Portugal, Sweden and Japan. The onset of symptoms is usually between 25 and 35 years of age, but late-onset families are also known. The most common clinical symptoms are polyneuropathy of the lower limbs, rhythmological disturbances and diarrhea/obstipation. TTR amyloid is predominantly produced in the liver; only as few as 5% are synthesized in the retina and choroid plexus. Therefore, liver transplantation has become widely accepted as the ultimate curative treatment of this disease in order to prevent the ultimately fatal outcome and ameliorate disabling symptoms. Because of shortage of donor grafts, livers of FAP patients are used for domino liver transplantation. Last year, a new therapeutic option was approved by the European Medical Authority (EMA) for therapy of early-stage FAP. The first results of a multicenter-controlled trial have been published and show a benefit in patients with an early stage of disease regarding neurological symptoms as well as modified BMI. There are several other pharmacologic approaches that have been reported in the last years which may lead to stabilization of the TTR tetramer. Therefore, this might be the beginning of new therapeutic options with pharmacological therapies in patients with FAP.

Keywords:
Familial amyloid polyneuropathy, Amyloidosis, Neuropathy
1.
Robbins J: Thyroxine-binding proteins. Prog Clin Biol Res 1976;5:331-355.
2.
Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL: GenBank: update. Nucleic Acids Res 2004;32:D23-D26.
3.
Andrade C: A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952;75:408-427.
4.
Roberts JR, et al: Amyloidosis: transthyretin-related. Medscape, 2009. http://emedicine.medscape.com/article/335301 (accessed August 2011).
5.
Ando Y, Nakamura M, Araki S: Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-1062.
6.
Benson MD, Kincaid JC: The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007;36:411-423.
7.
Sekijima Y, Kelly JW, Ikeda S: Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des 2008;14:3219-3230.
8.
Sousa A, Coelho T, Barros J, Sequeiros J: Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal). Am J Med Genet 1995;60:512-521.
9.
Holmgren G, Wikström L, Lundgren HE, Suhr OB: Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins. J Intern Med 2004;256:453-456.
10.
Kato-Motozaki Y, Ono K, Shima K, Morinaga A, Machiya T, Nozaki I, Shibata-Hamaguchi A, Furukawa Y, Yanase D, Ishida C, Sakajiri K, Yamada M: Epidemiology of familial amyloid polyneuropathy in Japan: identification of a novel endemic focus. J Neurol Sci 2008;270:133-140.
11.
Picken MM: Amyloidosis - where are we now and where are we heading? Arch Pathol Lab Med 2010;134:545-551.
12.
Kumar P, Clark M: Chapter 19; in: Kumar and Clark's Clinical Medicine 2009, ed 7. Philadelphia, Saunders, 2009.
13.
Merlini G, Westermark P: The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004;255:159-178.
14.
Zeldenrust SR: ATTR: diagnosis, prognosis, and treatment; in Gertz MA, Rajkumar SV (eds): Amyloidosis: Diagnosis and Treatment. Totowa, Humana Press, 2010.
15.
Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A: Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 2010;7:398-408.
16.
Coutinho P, De Silva AM, Lima JL, Barbosa AR: Forty years of experience with type I amyloid neuropathy: review of 483 cases; in Glenner GG, Costa PP, de Freitas AF (eds): Amyloid and Amyloidosis. Amsterdam, Excerpta Medica, 1980, pp 88-98.
17.
Benson M: The hereditary amyloidoses. Best Pract Res Clin Rhematol 2003;17:909-927.
18.
Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, Galle PR, Otto G: Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl 2010;16:314-323.
19.
Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G: Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 2007;69:693-698.
20.
de Carvalho M, Conceicao I, Bentes C, Luis ML: Long-term quantitative evaluation of liver transplantation in familial amyloid polyneuropathy (Portuguese V30M). Amyloid 2002;9:126-133.
21.
Altland K: Life style and transthyretin-type amyloidosis: what could be the links? Acta Histochem 2006;108:227.
22.
Familial Amyloidotic Polyneuropathy World Transplant Registry. www.fapwtr.org.
23.
Suhr OB, Friman S, Ericzon BG: Early liver transplantation improves familial amyloidotic polyneuropathy patients' survival. Amyloid 2005;12:233-238.
24.
Telles-Correia D, Barbosa A, Mega I, Mateus E, Monteiro E: When does quality of life improve after liver transplantation? A longitudinal prospective study. Transplant Proc 2009;41:904-905.
25.
Yamamoto S, Wilczek HE, Nowak G, Larsson M, Oksanen A, Iwata T, et al: Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007;7:2597-2604.
26.
Barreiros AP, Geber C, Birklein F, Galle PR, Otto G: Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl 2010;16:109.
27.
Connelly S, Choi S, Johnson SM, Kelly JW, Wilson IA: Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. Curr Opin Struct Biol 2010;20:54-62.
28.
Hammarstrom P, Wiseman RL, Powers ET, Kelly JW: Prevention of transthyretin amyloid disease by changing protein misfolding energetics. Science 2003;299:713-716.
29.
Coelho T, Maia LF, Martins da Silva A, Cruz MW, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceiçao I, Schmidt H, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR: Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785-792.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.